Glaukos Corporation (GKOS)

112,60 -1,03 (-0,91%) Al cierre: 04:00PM EDT

Glaukos Corporation

One Glaukos Way
Aliso Viejo, CA 92656
United States
949 367 9600
https://www.glaukos.com

Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 907

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Thomas William Burns	Chairman & CEO	774,9k	24,98M	1961
Mr. Joseph E. Gilliam	President & COO	1,18M	4,01M	1976
Mr. Alex R. Thurman	Senior VP & CFO	621,24k	N/A	1970
Dr. Tomas Navratil Ph.D.	Chief Development Officer	866,18k	N/A	1977
Dr. Mory Gharib Ph.D.	Co-Founder	N/A	N/A	N/A
Mr. Christopher William Lewis	Vice President of Investor Relations & Corporate Affairs	N/A	N/A	N/A
Ms. Diana A. Scherer	VP of Compliance & Deputy General Counsel	N/A	N/A	N/A
Ms. Michele M. Allegretto	Senior Vice President of Human Resources	N/A	N/A	N/A
Mr. Chris M. Calcaterra	Executive Vice President of Global Commercial Operations	198,66k	N/A	1960
Ms. Jane E. Rady	Senior Vice President of Corporate Strategy & Business Development	N/A	N/A	1948

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Gobierno corporativo

El ISS Governance QualityScore de Glaukos Corporation, a día 1 de junio de 2024, es 6. Las puntuaciones base son Auditoría: 3; Tablero: 7; Derechos de los accionistas: 8; Compensación: 5.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.